



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BR720 : Breast cancer with breast tissue array, including pathology grade, TNM and clinical satge (reference AJCC 7th version), 72 cases/72 cores

Microarray Panel	Breast carcinoma with breast tissue microarray, containing 56 cases of invasive carcinoma of no special type, 12 medullary carcinoma, 2 adjacent normal breast tissue, 1 cancer adjacent breast tissue, 1 breast tissue, single core per case	
Cores	72	
Cases	72	
Row number	8	
Column number	9	
Core Diameter (mm)	1.5	
Thickness (µm)	5	
Tissue Array Type	FFPE	
Species	Human	
Applications	Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.	
Notes	1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours. In the following specsheet, “**” means invalid core; “-” means no applicable or negative in IHC markers.	

	1	2	3	4	5	6	7	8	9
A	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
B	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
C	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
D	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
E	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
F	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
G	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre
H	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Bre	Adr

Legend: Bre - Breast

● - AT, ● - Malignant tumor, ● - Malignant tumor (stage I), ● - Malignant tumor (stage IIA), ● - Malignant tumor (stage IIB), ● - Malignant tumor (stage IIIA), ● - Malignant tumor (stage IIIB), ● - NAT, ● - Normal tissue

, tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Image
A1	1	35	F	Breast	Invasive carcinoma of no special type	T1N0M0	1	I	Malignant	
A2	2	28	F	Breast	Invasive carcinoma of no special type	T1N1M0	1--2	IIA	Malignant	
A3	3	42	F	Breast	Invasive carcinoma of no special type	T2N1M0	2	IIB	Malignant	
A4	4	38	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
A5	5	74	F	Breast	Invasive carcinoma of no special type	T4N0M0	2	IIIB	Malignant	
A6	6	54	F	Breast	Invasive carcinoma of no special type	T3N0M0	2	IIB	Malignant	
A7	7	48	F	Breast	Invasive carcinoma of no special type	T4N2M0	2	IIIB	Malignant	
A8	8	52	F	Breast	Invasive carcinoma of no special type	T3N0M0	2	IIB	Malignant	
A9	9	38	F	Breast	Invasive carcinoma of no special type	T2N1M0	2	IIB	Malignant	

	B1	10	50	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
	B2	11	48	F	Breast	Invasive carcinoma of no special type	T4N0M0	2	IIIB	Malignant	
	B3	12	44	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
	B4	13	42	F	Breast	Invasive carcinoma of no special type	T4N0M0	2	IIIB	Malignant	
	B5	14	48	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
	B6	15	45	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
	B7	16	47	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
	B8	17	44	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
	B9	18	53	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
	C1	19	61	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
	C2	20	50	F	Breast	Invasive carcinoma of no special type	T4N0M0	2	IIIB	Malignant	
	C3	21	39	F	Breast	Invasive carcinoma of no special type	T2N1M0	2	IIB	Malignant	
	C4	22	48	F	Breast	Invasive carcinoma of no special type	T2N2M0	2	IIIA	Malignant	
	C5	23	45	F	Breast	Invasive carcinoma of no special type	T4N0M0	2	IIIB	Malignant	
	C6	24	42	F	Breast	Invasive carcinoma of no special type	T3N0M0	2	IIB	Malignant	
	C7	25	48	F	Breast	Invasive carcinoma of no special type	T4N1M0	2	IIIB	Malignant	
	C8	26	79	F	Breast	Invasive carcinoma of no special type	T4N0M0	2	IIIB	Malignant	
	C9	27	58	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
	D1	28	43	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
	D2	29	37	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
	D3	30	54	F	Breast	Invasive carcinoma of no special type	T3N0M0	2	IIB	Malignant	
	D4	31	47	F	Breast	Invasive carcinoma of no special type	T4N0M0	2	IIIB	Malignant	
	D5	32	76	F	Breast	Invasive carcinoma of no special type	T4N0M0	2	IIIB	Malignant	
	D6	33	59	F	Breast	Medullary carcinoma	T3N0M0	-	IIB	Malignant	
	D7	34	46	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
	D8	35	57	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
	D9	36	41	F	Breast	Invasive carcinoma of no special type	T2N0M0	3	IIA	Malignant	
	E1	37	68	F	Breast	Invasive carcinoma of no special type	T2N0M0	2	IIA	Malignant	
	E2	38	55	F	Breast	Invasive carcinoma of no special type	T4N1M0	2	IIIB	Malignant	
	E3	39	51	F	Breast	Invasive carcinoma of no special type	T2N0M0	3	IIA	Malignant	
	E4	40	48	F	Breast	Invasive carcinoma of no special type	T2N0M0	3	IIA	Malignant	
	E5	41	45	F	Breast	Invasive carcinoma of no special type	T2N0M0	3	IIA	Malignant	
	E6	42	43	F	Breast	Invasive carcinoma of no special type	T1N0M0	2	I	Malignant	
	E7	43	59	F	Breast	Invasive carcinoma of no special type with ... tly mucinous carcinoma	T2N2M0	2	IIIA	Malignant	
	E8	44	40	F	Breast	Invasive carcinoma of no special type	T3N0M0	3	IIB	Malignant	
	E9	45	41	F	Breast	Invasive carcinoma of no special type	T2N0M0	2--3	IIA	Malignant	
	F1	46	37	F	Breast	Invasive carcinoma of no special type	T2N1M0	2--3	IIB	Malignant	
	F2	47	49	F	Breast	Medullary carcinoma	T2N2M0	-	IIIA	Malignant	
	F3	48	45	F	Breast	Invasive carcinoma of no special type	T3M0N0	3	IIB	Malignant	
	F4	49	32	F	Breast	Invasive carcinoma of no special type	T1N1M0	3	IIA	Malignant	
	F5	50	52	F	Breast	Invasive carcinoma of no special type	T2N0M0	3	IIA	Malignant	
	F6	51	38	F	Breast	Invasive carcinoma of no special type	T3N0M0	3	IIB	Malignant	
	F7	52	55	F	Breast	Invasive carcinoma of no special type	T2N1M0	3	IIB	Malignant	
	F8	53	46	F	Breast	Invasive carcinoma of no special type	T3N0M0	3	IIB	Malignant	
	F9	54	51	F	Breast	Invasive carcinoma of no special type	T4N1M0	3	IIIB	Malignant	
	G1	55	31	F	Breast	Invasive carcinoma of no special type	T3N0M0	3	IIB	Malignant	
	G2	56	38	F	Breast	Invasive carcinoma of no special type (spars e)	T4N0M0	3	IIIB	Malignant	
	G3	57	52	F	Breast	Invasive carcinoma of no special type	T2N0M0	3	IIA	Malignant	
	G4	58	54	F	Breast	Invasive carcinoma of no special type	T2N1M0	2	IIB	Malignant	
	G5	59	52	F	Breast	Medullary carcinoma	T2N0M0	-	IIA	Malignant	
	G6	60	56	F	Breast	Medullary carcinoma	T2N0M0	-	IIA	Malignant	
	G7	61	46	F	Breast	Medullary carcinoma	T2N0M0	-	IIA	Malignant	
	G8	62	35	F	Breast	Medullary carcinoma	T3N0M0	-	IIB	Malignant	
	G9	63	40	F	Breast	Medullary carcinoma	T1N0M0	-	I	Malignant	
	H1	64	64	F	Breast	Medullary carcinoma	T2N0M0	-	IIA	Malignant	

H2	65	48	F	Breast	Medullary carcinoma	T4N0M0	-	IIIB	Malignant	
H3	66	39	F	Breast	Medullary carcinoma	T2N0M0	-	IIA	Malignant	
H4	67	59	F	Breast	Medullary carcinoma	T2N0M0	-	IIA	Malignant	
H5	68	63	F	Breast	Medullary carcinoma	T2N1M0	-	IIB	Malignant	
H6	69	43	F	Breast	Adjacent normal breast tissue	-	-	-	NAT	
H7	70	38	F	Breast	Adjacent normal breast tissue	-	-	-	NAT	
H8	71	34	F	Breast	Cancer adjacent breast tissue	-	-	-	AT	
H9	72	50	F	Breast	Breast tissue	-	-	-	Normal	
-	0	42	M	Adrenal gland	Pheochromocytoma (tissue marker)		-		Malignant	



TNM grading:

T - Primary tumor

- Tx - Primary tumor cannot be assessed
- T0 - No evidence of primary tumor
- Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
- T1 - Tumor invades submucosa
- T2 - Tumor invades muscularis propria
- T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
- T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes

- Nx - Regional lymph nodes cannot be assessed
- N0 - No regional lymph node metastasis
- N1 - Metastasis in 1 to 3 regional lymph nodes
- N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis

- Mx - Distant metastasis cannot be assessed
- M0 - No distant metastasis
- M1 - Distant metastasis



UK & Rest of the World
AMS Biotechnology (Europe) Ltd
184 Park Drive, Milton Park
Abingdon, OX14 4SE, UK
T: +44 (0)1235 828 200
F: +44 (0)1235 820 482



North America
amsbio LLC
1035 Cambridge Street,
Cambridge, MA 02141
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218



Germany
AMS Biotechnology (Europe) Ltd
Bockenheimer Landstr. 17/19
60325 Frankfurt/Main
T: +49 (0) 69 779099
F: +49 (0) 69 13376880



Switzerland
AMS Biotechnology (Europe) Ltd
Centro Nord-Sud 2E
CH-6934 Bioggio-Lugano
T: +41(0) 91 604 55 22
F: +41(0) 91 605 17 85